Novo Nordisk reported DKK208.7B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Bausch Health Companies USD 7.41B 886M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Novo Nordisk DKK 31.89B 145.42B Jun/2026
Pacira USD 10.3B 9.68B Sep/2026
Sanofi EUR 33.21B 1.68B Sep/2026
Supernus Pharmaceuticals USD 711.21M 12.28M Sep/2026